Stryker (SYK) Akcija Kursas
Stryker Kursas
Per pastaruosius 19 metus Stryker pajamos augo 8,4 % kasmet ir pasiekė 25,12 mlrd. USD. Pelnas akcijai augo 8,2 % per metus per pastaruosius 19 metus. Stryker grynoji marža 12,9 % yra išaugo palyginti su 11,7 % prieš kelerius metus. Esama kaina dividendo pajamingumas yra apie 1,08 %. Išmokų koeficientas yra apie 40 % pelno. Dividendas augo 15,5 % per metus per pastaruosius 19 metus. Stryker 12 mėn. konsensuso tikslinė kaina yra 364,50 USD, apie virš kursą 15,4 %. Iš 35 analitikų 27 rekomenduoja pirkti — bendras konsensusas yra Pirkti.
Stryker akcijos kaina
Gaukite šiuos duomenis per Eulerpool API
100 000 užklausų/mėn. nemokamai · be kortelės
Stryker akcija ir akcijų analizė
Dažnai užduodami klausimai apie Stryker akciją
The business model of Stryker Corp focuses on providing innovative medical technologies and solutions worldwide. As a leading medical technology company, Stryker Corp specializes in products and services across various segments, including orthopedics, medical and surgical, neurotechnology, and spine. With a strong emphasis on research and development, Stryker Corp strives to deliver advanced and effective healthcare solutions to improve patient outcomes. The company's commitment to innovation, quality, and customer satisfaction has made it a trusted name in the medical industry. Stryker Corp's business model revolves around leveraging its expertise and cutting-edge technologies to meet the evolving needs of healthcare professionals and enhance the lives of patients.
Stryker Corp is primarily active in the healthcare industry.
The main competitors of Stryker Corp in the market are Johnson & Johnson, Medtronic, Zimmer Biomet Holdings, and Boston Scientific.
Stryker Corp is a renowned American medical technology company established in 1941. With over 80 years of experience, Stryker has evolved into a global leader specializing in surgical equipment and orthopedic implants. The company's roots trace back to its founding by Dr. Homer Stryker, an innovative orthopedic surgeon who developed various medical devices. Today, Stryker Corp offers a wide range of products across multiple medical disciplines, including reconstructive devices, neurotechnology, spine systems, and more. The company's commitment to innovation, coupled with strategic acquisitions, has solidified its position as a trusted name in the medical industry.
Stryker Corp has achieved significant milestones throughout its history. A major accomplishment for the company was the development and introduction of the first-ever surgical navigation system, the Navigation System II. This technology revolutionized surgical procedures by providing real-time imaging and guidance to surgeons, improving precision and patient outcomes. Another notable milestone for Stryker Corp was the acquisition of Howmedica, a leading orthopedic company, in 1998. This strategic move further strengthened Stryker Corp's position in the medical technology industry, enhancing its product portfolio and global presence. Over the years, the company has continued to innovate and has been recognized for its advancements in medical devices and solutions.
Stryker Corp is primarily present in various countries and regions worldwide. Some of the key locations include the United States, where the company is headquartered in Kalamazoo, Michigan. Additionally, Stryker has a significant presence in Europe, with operations in countries such as Germany, France, the United Kingdom, Italy, and Switzerland. The company is also active in the Asia-Pacific region, specifically in countries like China, Japan, India, and Australia. With its global reach, Stryker Corp ensures its innovative medical technologies and products are available to healthcare professionals and patients across different parts of the world.
Stryker Corp represents values of innovation, integrity, and excellence in the medical technology industry. The company's corporate philosophy centers around delivering high-quality products and services that improve patient outcomes and enhance healthcare providers' capabilities. By continually investing in research and development, Stryker strives to introduce cutting-edge solutions that address critical healthcare needs and promote sustainable growth. With a commitment to ethical business practices and global collaboration, Stryker focuses on delivering value to its stakeholders, including healthcare professionals, patients, employees, and shareholders. Stryker Corp's dedication to advancing medical technology and improving lives embodies its core values and corporate philosophy.
Analitikai šiuo metu nustato vidutinę Stryker akcijos tikslinę kainą 356,69 USD (mediana: 364,50 USD), t. y. +12,9 % palyginti su paskutine kaina. Konsensusas pagrįstas 35 analitikų reitingais.
35 analitikai šiuo metu vertina Stryker akciją: 27 rekomenduoja pirkti, 8 laikyti ir 0 parduoti. 2026 m. analitikai tikisi, kad Stryker gaus 26,82 mlrd. USD pajamų ir 14,84 USD pelno akcijai.
Pagal dabartinį kursą Stryker akcija kainuoja 287,79 EUR (315,82 USD).
Stryker akcija (SYK) kotiruojama 12 biržose, įskaitant: NYSE (SYK), London (0R2S.L), SIX (Zürich) (SYK.SW), XETRA (SYK.DE), Frankfurt (SYK.F), München (SYK.MU), Stuttgart (SYK.SG), Düsseldorf (SYK.DU).
Stryker Corp is a US-American company that specializes in the manufacturing and sale of medical devices, implantable products, and medical services. The company was founded in 1941 and has since become a leading company in the medical technology industry. Stryker has four business segments, namely Medical Devices, Orthopedics, Medical and Surgical Instruments, and Neurotechnology and Spine Products. In the Medical Devices segment, Stryker offers a wide range of products including endoscopy devices, respiratory devices, patient monitoring devices, neurological monitoring devices, and medical lighting systems. These products are used in hospitals and clinical facilities for patient diagnosis and treatment. In Orthopedics, Stryker is one of the world leaders in implants and instruments for joint surgery. The company offers products for the hip, knee, shoulder, wrist, and other joints. Stryker has also taken a leading role in introducing robotics in surgery in this field. The Mako robot allows for precise implantations, enabling patients to have faster recovery and improved quality of life. The Medical and Surgical Instruments segment includes a wide range of instruments for surgery, including surgical saws, scalpels, forceps, and other instruments for various surgical procedures. These instruments are used by physicians for a variety of surgical interventions. In the Neurotechnology and Spine Products segment, Stryker develops and distributes products for spinal surgery, including implants for intervertebral discs and for stabilization of the cervical and lumbar spine. In addition to selling products, Stryker also offers medical services. This includes consulting and support for the implementation of products and systems in hospitals and medical facilities. Technical support and customer service are also part of the offerings. Stryker's business model is based on its ability to develop and produce innovative and high-quality products for the medical field. The company emphasizes close collaboration with medical professionals to ensure that the offered products meet the requirements of the practice and enable optimal treatment for patients. The company also strives to continuously improve its products and develop new technologies. In particular, the introduction of robotics in surgery offers Stryker significant growth opportunities as it has the potential for higher efficiency, precision, and better treatment outcomes. Overall, Stryker is a leading company in the medical technology industry, specializing in the development of innovative products and the provision of high-quality medical services. The company has a wide range of products in various business segments, including Medical Devices, Orthopedics, Medical and Surgical Instruments, and Neurotechnology and Spine Products. Stryker's business model is based on serving medical professionals with high-quality products and services and developing innovative technologies to achieve even better treatment outcomes for patients.
tikėtina pelnas Stryker yra 26,82 mlrd. USD. Šis skaičius grindžiamas dabartiniais finansiniais duomenimis ir atspindi įmonės verslo rezultatus.
tikėtina grynasis pelnas Stryker yra 5,73 mlrd. USD. Grynasis pelnas atspindi įmonės pelningumą po visų išlaidų atimties.
Kainų ir nuomos santykis (KGV) Stryker šiuo metu yra 21,29. KGV lygina dabartinę akcijos kainą su pelnu už akciją ir padeda investuotojams įvertinti Stryker akcijos vertę.
Kainų ir pardavimų santykis (KUV) Stryker šiuo metu yra 4,55. KUV lygina rinkos kapitalizaciją su metinėmis pajamomis ir yra Stryker akcijos įvertinimo metrika.
Eulerpool kokybės balas Stryker yra 7/10.
Stryker ISIN yra US8636671013. ISIN (International Securities Identification Number) yra pasaulinė unikali vertybinių popierių identifikacijos sistema.
Stryker WKN yra 864952. WKN (Wertpapierkennnummer) yra šešiaženklė vokiška vertybinių popierių identifikacijos sistema.
Stryker prekybos žymė yra SYK. Ši biržos žymė naudojama Stryker akcijoms prekiauti biržoje.
Stryker akcija
Stryker Pagrindiniai konkurentai
Stryker Biržos simbolis
Stryker FIGI
Visos Stryker pagrindinės charakteristikos ir giluminė analizė
Mūsų akcijų analizė Stryker akcijai apima svarbius finansinius rodiklius, tokius kaip apyvarta, pelnas, P/E santykis, P/S santykis, EBIT, taip pat informaciją apie dividendes. Be to, mes nagrinėjame aspektus, tokius kaip akcijos, rinkos kapitalizacija, skolos, nuosavas kapitalas ir įsipareigojimai Stryker. Jei ieškote išsamesnės informacijos šiais klausimais, mūsų poskyriuose galite rasti išsamias analizes: